On September 1, 2016 Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) reported that a poster detailing preliminary results from the Company’s Phase 1A study in healthy volunteers evaluating oral non-covalent BTK-inhibitor SNS-062 will be presented at the European School of Haematology’s 2nd International Conference on New Concepts in B-Cell Malignancies being held September 9-11, 2016, at the Estoril Congress Centre in Estoril, Portugal (Press release, Sunesis, SEP 1, 2016, View Source [SID:1234514866]). Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The details for the poster presentation are as follows:
Date & Time: Saturday, September 10, 2016, from 6:50 p.m. to 8:20 p.m. Central European Time
Poster Title: A Phase 1a Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects: Preliminary Results
The poster will be available on the Sunesis website following the presentation.